Characterization of the enzymatic activity of human kallikrein 6: Autoactivation, substrate specificity, and regulation by inhibitors

Biochemical and Biophysical Research Communications

Volumn 307, Issue 4, 2003, Pages 948-955

  Magklara, Angeliki ^a,b   Mellati, Ali A ^a   Wasney, Gregory A ^a   Little, Sheila P ^c   Sotiropoulou, Georgia ^d   Becker, Gerald W ^e   Diamandis, Eleftherios P ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF PATRAS   (Greece)

^e Roche Diagnostics Corporation   (United States)

Author keywords

Cancer; Enzymatic activity; Enzymatic cascade; Human kallikrein 6; Human kallikreins; Serine proteases

Indexed keywords

AMYLOID PRECURSOR PROTEIN; ANTITHROMBIN III; ARGININE; COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRINOGEN; KALLIKREIN; KALLIKREIN 6; LYSINE; PROLINE; SERINE; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; AMINO TERMINAL SEQUENCE; ARTICLE; CANCER INVASION; CONTROLLED STUDY; EMBRYO; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; HUMAN CELL; METASTASIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN INTERACTION; REGULATORY MECHANISM;

EID: 0037767804     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-291X(03)01271-3     Document Type: Article

References (47)

1. Yousef G.M., Diamandis E.P. Human kallikreins: common structural features, sequence analysis and evolution. Curr. Genomics. 4:2003;147-165.
2. Diamandis E.P. Prostate-specific antigen: its usefulness in clinical medicine. Trends Endocrinol. Metab. 9:1998;310-316.
3. Diamandis E.P., Yousef G.M. Human tissue kallikreins: a family of new cancer biomarkers. Clin. Chem. 48:2002;1198-1205.
4. Yousef G.M., Diamandis E.P. Human tissue kallikreins: a new enzymatic cascade pathway? Biol. Chem. 383:2002;1045-1057.
5. Lilja H., Christensson A., Dahlen U., Matikainen M.T., Nilsson O., Pettersson K., Lovgren T. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin. Chem. 37:1991;1618-1625.
6. Stenman U.H., Leinonen J., Alfthan H., Rannikko S., Tuhkanen K., Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 51:1991;222-226.
7. Cao Y., Lundwall A., Gadaleanu V., Lilja H., Bjartell A. Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. Am. J. Pathol. 161:2002;2053-2063.
8. Zhang W.M., Finne P., Leinonen J., Salo J., Stenman U.H. Determination of prostate-specific antigen complexed to alpha(2)-macroglobulin in serum increases the specificity of free to total PSA for prostate cancer. Urology. 56:2000;267-272.
9. Deperthes D., Chapdelaine P., Tremblay R.R., Brunet C., Berton J., Hebert J., Lazure C., Dube J.Y. Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma. Biochim. Biophys. Acta. 1245:1995;311-316.
10. Heeb M.J., Espana F. alpha2-macroglobulin and C1-inactivator are plasma inhibitors of human glandular kallikrein. Blood Cells Mol. Dis. 24:1998;412-419.
11. Grauer L.S., Finlay J.A., Mikolajczyk S.D., Pusateri K.D., Wolfert R.L. Detection of human glandular kallikrein, hK2, as its precursor form and in complex with protease inhibitors in prostate carcinoma serum. J. Androl. 19:1998;407-411.
12. 2+ and extracellular protease inhibitors. Eur. J. Biochem. 262:1999;781-789.
13. Anisowicz A., Sotiropoulou G., Stenman G., Mok S.C., Sager R. A novel protease homolog differentially expressed in breast and ovarian cancer. Mol. Med. 2:1996;624-636.
14. Yamashiro K., Tsuruoka N., Kodama S., Tsujimoto M., Yamamura Y., Tanaka T., Nakazato H., Yamaguchi N. Molecular cloning of a novel trypsin-like serine protease (neurosin) preferentially expressed in brain. Biochim. Biophys. Acta. 1350:1997;11-14.
15. Little S.P., Dixon E.P., Norris F., Buckley W., Becker G.W., Johnson M., Dobbins J.R., Wyrick T., Miller J.R., MacKellar W., Hepburn D., Corvalan J., McClure D., Liu X., Stephenson D., Clemens J., Johnstone E.M. Zyme, a novel and potentially amyloidogenic enzyme cDNA isolated from Alzheimer's disease brain. J. Biol. Chem. 272:1997;25135-25142.
16. Yousef G.M., Luo L.Y., Scherer S.W., Sotiropoulou G., Diamandis E.P. Molecular characterization of zyme/protease M/neurosin (PRSS9), a hormonally regulated kallikrein-like serine protease. Genomics. 62:1999;251-259.
17. Diamandis E.P., Yousef G.M., Soosaipillai A.R., Grass L., Porter A., Little S., Sotiropoulou G. Immunofluorometric assay of human kallikrein 6 (zyme/protease M/neurosin) and preliminary clinical applications. Clin. Biochem. 33:2000;369-375.
18. Petraki C.D., Karavana V.N., Skoufogiannis P.T., Little S.P., Howarth D.J., Yousef G.M., Diamandis E.P. The spectrum of human kallikrein 6 (zyme/protease M/neurosin) expression in human tissues as assessed by immunohistochemistry. J. Histochem. Cytochem. 49:2001;1431-1441.
19. Ogawa K., Yamada T., Tsujioka Y., Taguchi J., Takahashi M., Tsuboi Y., Fujino Y., Nakajima M., Yamamoto T., Akatsu H., Mitsui S., Yamaguchi N. Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease. Psychiatr. Clin. Neurosci. 54:2000;419-426.
20. Zarghooni M., Soosaipillai A., Grass L., Scorilas A., Mirazimi N., Diamandis E.P. Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients. Clin. Biochem. 35:2002;225-231.
21. Diamandis E.P., Yousef G.M., Petraki C., Soosaipillai A.R. Human kallikrein 6 as a biomarker of Alzheimer's disease. Clin. Biochem. 33:2000;663-667.
22. Mitsui S., Tsuruoka N., Yamashiro K., Nakazato H., Yamaguchi N. A novel form of human neuropsin, a brain-related serine protease, is generated by alternative splicing and is expressed preferentially in human adult brain. Eur. J. Biochem. 260:1999;627-634.
23. Scarisbrick I.A., Blaber S.I., Lucchinetti C.F., Genain C.P., Blaber M., Rodriguez M. Activity of a newly identified serine protease in CNS demyelination. Brain. 125:2002;1283-1296.
24. Diamandis E.P., Yousef G.M., Soosaipillai A.R., Bunting P. Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma. Clin. Biochem. 33:2000;579-583.
25. Tanimoto H., Underwood L.J., Shigemasa K., Parmley T.H., O'Brien T.J. Increased expression of protease M in ovarian tumors. Tumour Biol. 22:2001;11-18.
26. Hoffman B.R., Katsaros D., Scorilas A., Diamandis P., Fracchioli S., Rigault De La Longrais I.A., Colgan T., Puopolo M., Giardina G., Massobrio M., Diamandis E.P. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker. Br. J. Cancer. 87:2002;763-771.
27. Gaffney P.J. Fibrin degradation products. A review of structures found in vitro and in vivo. Ann. N. Y. Acad. Sci. 936:2001;594-610.
28. Gomis-Ruth F.X., Bayes A., Sotiropoulou G., Pampalakis G., Tsetsenis T., Villegas V., Aviles F.X., Coll M. The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family. J. Biol. Chem. 277:2002;27273-27281.
29. Bernett M.J., Blaber S.I., Scarisbrick I.A., Dhanarajan P., Thompson S.M., Blaber M. Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277:2002;24562-24570.
30. Shimizu C., Yoshida S., Shibata M., Kato K., Momota Y., Matsumoto K., Shiosaka T., Midorikawa R., Kamachi T., Kawabe A., Shiosaka S. Characterization of recombinant and brain neuropsin, a plasticity-related serine protease. J. Biol. Chem. 273:1998;11189-11196.
31. Yoshida S., Shiosaka S. Plasticity-related serine proteases in the brain (review). Int. J. Mol. Med. 3:1999;405-409.
32. Yoshida S., Taniguchi M., Hirata A., Shiosaka S. Sequence analysis and expression of human neuropsin cDNA and gene. Gene. 213:1998;9-16.
33. Magklara A., Scorilas A., Katsaros D., Massobrio M., Yousef G.M., Fracchioli S., Danese S., Diamandis E.P. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin. Cancer Res. 7:2001;806-811.
34. Underwood L.J., Tanimoto H., Wang Y., Shigemasa K., Parmley T.H., O'Brien T.J. Cloning of tumor-associated differentially expressed gene-14, a novel serine protease overexpressed by ovarian carcinoma. Cancer Res. 59:1999;4435-4439.
35. Vindigni A., Dang Q.D., Di Cera E. Site-specific dissection of substrate recognition by thrombin. Nat. Biotechnol. 15:1997;891-895.
36. Del Rosso M., Fibbi G., Pucci M., D'Alessio S., Del Rosso A., Magnelli L., Chiarugi V. Multiple pathways of cell invasion are regulated by multiple families of serine proteases. Clin. Exp. Metastasis. 19:2002;193-207.
37. Blasi F., Carmeliet P. uPAR: a versatile signalling orchestrator. Nat. Rev. Mol. Cell. Biol. 3:2002;932-943.
38. Duffy M.J. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies. Clin. Chem. 48:2002;1194-1197.
39. Selkoe D.J. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 399:1999;A23-31.
40. Lee E.B., Skovronsky D.M., Abtahian F., Doms R.W., Lee V.M. Secretion and intracellular generation of truncated Abeta in beta-aite amyloid-beta precursor protein-cleaving enzyme expressing human neurons. J. Biol. Chem. 278:2003;4458-4466.
41. Ledesma M.D., Da Silva J.S., Crassaerts K., Delacourte A., De Strooper B., Dotti C.G. Brain plasmin enhances APP alpha-cleavage and Abeta degradation and is reduced in Alzheimer's disease brains. EMBO Rep. 1:2000;530-535.
42. Longas M.O., Finlay T.H. The covalent nature of the human antithrombin III-thrombin bond. Biochem. J. 189:1980;481-489.
43. Wilczynska M., Fa M., Karolin J., Ohlsson P.I., Johansson L.B., Ny T. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins. Nat. Struct. Biol. 4:1997;354-357.
44. Travis J., Salvesen G.S. Human plasma proteinase inhibitors. Annu. Rev. Biochem. 52:1983;655-709.
45. Chandra T., Stackhouse R., Kidd V.J., Robson K.J., Woo S.L. Sequence homology between human alpha 1-antichymotrypsin, alpha 1-antitrypsin, and antithrombin III. Biochemistry. 22:1983;5055-5061.
46. Mast A.E., Enghild J.J., Pizzo S.V., Salvesen G. Analysis of the plasma elimination kinetics and conformational stabilities of native, proteinase-complexed, and reactive site cleaved serpins: comparison of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, antithrombin III, alpha 2-antiplasmin, angiotensinogen, and ovalbumin. Biochemistry. 30:1991;1723-1730.
47. Xi G., Reiser G., Keep R.F. The role of thrombin and thrombin receptors in ischemic, hemorrhagic and traumatic brain injury: deleterious or protective? J. Neurochem. 84:2003;3-9.